|
US3707475A
(en)
|
1970-11-16 |
1972-12-26 |
Pfizer |
Antiinflammatory imidazoles
|
|
DE3029376A1
(de)
|
1980-07-31 |
1982-03-18 |
Nepera Chemical Co. Inc., Harriman, N.Y. |
Verfahren zur herstellung von 2,4,5-tris-pyridylimidazolen
|
|
DE3486009T2
(de)
|
1983-09-09 |
1993-04-15 |
Takeda Chemical Industries Ltd |
5-pyridyl-1,3-thiazol-derivate, ihre herstellung und anwendung.
|
|
JP2722586B2
(ja)
|
1989-01-13 |
1998-03-04 |
大正製薬株式会社 |
インドリルイミダゾール誘導体
|
|
JP2808460B2
(ja)
|
1989-11-16 |
1998-10-08 |
大正製薬株式会社 |
イミダゾール誘導体
|
|
US6358932B1
(en)
|
1994-05-31 |
2002-03-19 |
Isis Pharmaceticals, Inc. |
Antisense oligonucleotide inhibition of raf gene expression
|
|
US5717100A
(en)
|
1995-10-06 |
1998-02-10 |
Merck & Co., Inc. |
Substituted imidazoles having anti-cancer and cytokine inhibitory activity
|
|
GB2306108A
(en)
|
1995-10-13 |
1997-04-30 |
Merck & Co Inc |
Treatment of Raf-mediated cancers with imidazole derivatives
|
|
US6268308B1
(en)
|
1996-08-27 |
2001-07-31 |
Syngenta Crop Protection, Inc. |
Herbicidal S-substituted 1,2,4,6-thiatriazines
|
|
JP4713698B2
(ja)
|
1997-03-05 |
2011-06-29 |
スージェン， インク． |
疎水性薬剤の処方
|
|
AR012634A1
(es)
|
1997-05-02 |
2000-11-08 |
Sugen Inc |
Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
|
|
GB9711650D0
(en)
|
1997-06-05 |
1997-07-30 |
Pfizer Ltd |
Compounds useful in therapy
|
|
GB9716557D0
(en)
|
1997-08-06 |
1997-10-08 |
Glaxo Group Ltd |
Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
|
|
US6022884A
(en)
|
1997-11-07 |
2000-02-08 |
Amgen Inc. |
Substituted pyridine compounds and methods of use
|
|
US6211177B1
(en)
|
1998-11-24 |
2001-04-03 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
|
|
WO2000042012A1
(en)
|
1999-01-13 |
2000-07-20 |
Bayer Corporation |
φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
|
|
US6548529B1
(en)
|
1999-04-05 |
2003-04-15 |
Bristol-Myers Squibb Company |
Heterocyclic containing biphenyl aP2 inhibitors and method
|
|
DE60001229T2
(de)
|
1999-04-09 |
2003-10-30 |
Smithkline Beecham Corp., Philadelphia |
Triarylimidazole
|
|
PL215901B1
(pl)
|
1999-04-15 |
2014-02-28 |
Bristol Myers Squibb Co |
Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
|
|
JP2000302680A
(ja)
|
1999-04-23 |
2000-10-31 |
Takeda Chem Ind Ltd |
脳保護剤
|
|
EP1218358B1
(en)
|
1999-09-23 |
2006-09-13 |
AstraZeneca AB |
Therapeutic quinazoline compounds
|
|
TR200201364T2
(tr)
|
1999-11-22 |
2002-10-21 |
Smithkline Beecham P. L. C. |
Yeni bileşikler.
|
|
WO2001052846A1
(en)
|
2000-01-18 |
2001-07-26 |
Vertex Pharmaceuticals Incorporated |
Gyrase inhibitors and uses thereof
|
|
EA005680B1
(ru)
|
2000-01-18 |
2005-04-28 |
Вертекс Фармасьютикалз Инкорпорейтед |
Ингибиторы гиразы и их применение для лечения бактериальной инфекции
|
|
AR029803A1
(es)
|
2000-02-21 |
2003-07-16 |
Smithkline Beecham Plc |
Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
|
|
ES2218391T3
(es)
|
2000-03-06 |
2004-11-16 |
Smithkline Beecham Plc |
Derivados de imidazol como inhibidores de raf-cinasa.
|
|
GB0005357D0
(en)
|
2000-03-06 |
2000-04-26 |
Smithkline Beecham Plc |
Compounds
|
|
GB0007405D0
(en)
|
2000-03-27 |
2000-05-17 |
Smithkline Beecham Corp |
Compounds
|
|
WO2001074811A2
(en)
|
2000-03-30 |
2001-10-11 |
Takeda Chemical Industries, Ltd. |
Substituted 1,3-thiazole compounds, their production and use
|
|
US6608053B2
(en)
|
2000-04-27 |
2003-08-19 |
Yamanouchi Pharmaceutical Co., Ltd. |
Fused heteroaryl derivatives
|
|
IL152848A0
(en)
|
2000-06-12 |
2003-06-24 |
Eisai Co Ltd |
1,2-dihydropyridine derivatives, pharmaceutical compositions containing the same and methods for the production thereof
|
|
DZ3401A1
(fr)
|
2000-07-19 |
2002-01-24 |
Warner Lambert Co |
Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
|
|
US6642252B2
(en)
|
2000-11-07 |
2003-11-04 |
Bristol-Myers Squibb Company |
Acid derivatives useful as serine protease inhibitors
|
|
ES2289004T3
(es)
|
2000-11-20 |
2008-02-01 |
Smithkline Beecham Corporation |
Nuevos compuestos.
|
|
AU2002232439A1
(en)
|
2000-11-29 |
2002-06-11 |
Glaxo Group Limited |
Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
|
|
WO2002064136A2
(en)
|
2001-01-26 |
2002-08-22 |
Chugai Seiyaku Kabushiki Kaisha |
Malonyl-coa decarboxylase inhibitors useful as metabolic modulators
|
|
CA2437248A1
(en)
|
2001-02-02 |
2002-08-15 |
Takeda Chemical Industries, Ltd. |
Jnk inhibitor
|
|
US20030009034A1
(en)
|
2001-03-22 |
2003-01-09 |
Neil Wishart |
Transition metal mediated process
|
|
JP2002338537A
(ja)
|
2001-05-16 |
2002-11-27 |
Mitsubishi Pharma Corp |
アミド化合物およびその医薬用途
|
|
GB0112348D0
(en)
|
2001-05-19 |
2001-07-11 |
Smithkline Beecham Plc |
Compounds
|
|
GB0129260D0
(en)
|
2001-12-06 |
2002-01-23 |
Eisai London Res Lab Ltd |
Pharmaceutical compositions and their uses
|
|
US8299108B2
(en)
|
2002-03-29 |
2012-10-30 |
Novartis Ag |
Substituted benzazoles and methods of their use as inhibitors of raf kinase
|
|
NZ535985A
(en)
|
2002-03-29 |
2007-04-27 |
Chiron Corp |
Substituted benzazoles and use thereof as RAF kinase inhibitors
|
|
AR039241A1
(es)
|
2002-04-04 |
2005-02-16 |
Biogen Inc |
Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
|
|
MXPA05001804A
(es)
|
2002-08-14 |
2005-05-27 |
Vertex Pharma |
Inhibidores de proteinas cinasas y usos de los mismos.
|
|
MXPA05002332A
(es)
|
2002-09-18 |
2005-06-08 |
Pfizer Prod Inc |
Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf).
|
|
JP4547271B2
(ja)
|
2002-09-18 |
2010-09-22 |
ファイザー・プロダクツ・インク |
トランスフォーミング増殖因子（ｔｇｆ）阻害剤としての新規イミダゾール化合物
|
|
US7531553B2
(en)
|
2003-03-21 |
2009-05-12 |
Amgen Inc. |
Heterocyclic compounds and methods of use
|
|
AR045944A1
(es)
|
2003-09-24 |
2005-11-16 |
Novartis Ag |
Derivados de isoquinolina 1.4-disustituidas
|
|
AU2004279427B2
(en)
|
2003-10-08 |
2008-07-03 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
|
PT1682126E
(pt)
|
2003-10-16 |
2009-10-02 |
Novartis Vaccines & Diagnostic |
Benzazois substituídos e sua utilização como inibidores da quinase raf
|
|
US8969372B2
(en)
|
2003-11-14 |
2015-03-03 |
Aptose Boisciences Inc. |
Aryl imidazoles and their use as anti-cancer agents
|
|
NZ549003A
(en)
|
2004-03-05 |
2009-07-31 |
Taisho Pharmaceutical Co Ltd |
Thiazole derivative as an ALK5 inhibitor
|
|
KR100749566B1
(ko)
|
2004-04-21 |
2007-08-16 |
이화여자대학교 산학협력단 |
Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
|
|
WO2005105814A1
(en)
|
2004-04-28 |
2005-11-10 |
Incyte Corporation |
Tetracyclic inhibitors of janus kinases
|
|
PE20060315A1
(es)
|
2004-05-24 |
2006-05-15 |
Irm Llc |
Compuestos de tiazol como moduladores de ppar
|
|
AU2005252110B2
(en)
|
2004-06-11 |
2008-09-04 |
Shionogi & Co., Ltd. |
5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-D] pyrimidine derivatives and related compounds for the treatment of cancer
|
|
US7453002B2
(en)
|
2004-06-15 |
2008-11-18 |
Bristol-Myers Squibb Company |
Five-membered heterocycles useful as serine protease inhibitors
|
|
GB0415364D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
GB0415367D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
GB0415365D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
CA2578630A1
(en)
|
2004-08-31 |
2006-03-09 |
Wen-Cherng Lee |
Pyrimidinylimidazoles as tgf-beta inhibitors
|
|
WO2006038734A1
(en)
|
2004-10-08 |
2006-04-13 |
Astellas Pharma Inc. |
Pyridazinone derivatives cytokines inhibitors
|
|
EP1804801A2
(en)
|
2004-10-15 |
2007-07-11 |
Biogen Idec MA, Inc. |
Methods of treating vascular injuries
|
|
JP2007246520A
(ja)
|
2006-02-15 |
2007-09-27 |
Takeda Yuichiro |
Ｒａｇｅ阻害剤
|
|
WO2007118149A2
(en)
|
2006-04-07 |
2007-10-18 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical Lollege |
Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers
|
|
DK2050749T3
(en)
|
2006-08-08 |
2018-01-08 |
Chugai Pharmaceutical Co Ltd |
PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF
|
|
WO2008071605A2
(en)
|
2006-12-15 |
2008-06-19 |
F. Hoffmann-La Roche Ag |
Methods of treating inflammatory diseases
|
|
EP2170848B1
(en)
|
2007-06-27 |
2014-10-22 |
AstraZeneca AB |
Pyrazinone derivatives and their use in the treatment of lung diseases
|
|
EP2167497A2
(en)
|
2007-06-29 |
2010-03-31 |
Sunesis Pharmaceuticals, Inc. |
Heterocyclic compounds useful as raf kinase inhibitors
|
|
AR067354A1
(es)
|
2007-06-29 |
2009-10-07 |
Sunesis Pharmaceuticals Inc |
Compuestos utiles como inhibidores de la raf quinasa
|
|
US20100240657A1
(en)
|
2007-07-02 |
2010-09-23 |
Boehringer Ingelheim International Gmbh |
Chemical compounds
|
|
EP2178866A2
(en)
|
2007-07-09 |
2010-04-28 |
AstraZeneca AB |
Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
|
|
JP2010533729A
(ja)
|
2007-07-17 |
2010-10-28 |
プレキシコン，インコーポレーテッド |
キナーゼ調節のための化合物と方法、及びそのための適応
|
|
JP5241834B2
(ja)
|
2007-07-19 |
2013-07-17 |
メルク・シャープ・アンド・ドーム・コーポレーション |
プロテインキナーゼ阻害剤としての複素環アミド化合物
|
|
US20110190280A1
(en)
|
2007-08-29 |
2011-08-04 |
George Adjabeng |
Thiazole And Oxazole Kinase Inhibitors
|
|
UY31322A1
(es)
|
2007-09-05 |
2009-04-30 |
|
Amidas heterocíclicas y sus métodos de uso-975
|
|
WO2009047163A1
(en)
|
2007-10-10 |
2009-04-16 |
F. Hoffmann-La Roche Ag |
Methods of treating inflammatory diseases
|
|
TW200940537A
(en)
|
2008-02-26 |
2009-10-01 |
Astrazeneca Ab |
Heterocyclic urea derivatives and methods of use thereof
|
|
US8865732B2
(en)
|
2008-03-21 |
2014-10-21 |
Novartis Ag |
Heterocyclic compounds and uses thereof
|
|
AU2009227013B2
(en)
|
2008-03-21 |
2013-01-10 |
Novartis Ag |
Novel heterocyclic compounds and uses therof
|
|
UA103319C2
(en)
|
2008-05-06 |
2013-10-10 |
Глаксосмитклайн Ллк |
Thiazole- and oxazole-benzene sulfonamide compounds
|
|
EP2297097A2
(en)
|
2008-06-11 |
2011-03-23 |
Irm Llc |
Compounds and compositions useful for the treatment of malaria
|
|
SI2324008T1
(sl)
|
2008-07-24 |
2012-08-31 |
Nerviano Medical Sciences Srl |
3,4-diarilpirazoli kot protein-kinazni inhibitorji
|
|
ES2522346T3
(es)
|
2008-08-22 |
2014-11-14 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de CDK
|
|
WO2010048149A2
(en)
|
2008-10-20 |
2010-04-29 |
Kalypsys, Inc. |
Heterocyclic modulators of gpr119 for treatment of disease
|
|
ES2663222T3
(es)
|
2008-12-19 |
2018-04-11 |
Vertex Pharmaceuticals Incorporated |
Derivados de pirazina útiles como inhibidores de la quinasa ATR
|
|
US8242260B2
(en)
|
2009-08-28 |
2012-08-14 |
Novartis Ag |
Compounds and compositions as protein kinase inhibitors
|
|
WO2011026911A1
(en)
|
2009-09-04 |
2011-03-10 |
Novartis Ag |
Bipyridines useful for the treatment of proliferative diseases
|
|
EP2498608A4
(en)
|
2009-11-10 |
2013-04-24 |
Glaxosmithkline Llc |
BENZOLSULFONAMIDE THIAZOL AND OXAZOLE COMPOUNDS
|
|
US9315491B2
(en)
|
2009-12-28 |
2016-04-19 |
Development Center For Biotechnology |
Pyrimidine compounds as mTOR and PI3K inhibitors
|
|
KR101778320B1
(ko)
|
2009-12-28 |
2017-09-13 |
잇반샤단호우징 화루마바레프로제쿠토 시엥기코우 |
1,3,4-옥사디아졸-2-카르복사미드 화합물
|
|
KR20110123657A
(ko)
|
2010-05-07 |
2011-11-15 |
에스케이케미칼주식회사 |
피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
|
|
US20130096149A1
(en)
|
2010-06-25 |
2013-04-18 |
Novartis Ag |
Heteroaryl compounds and compositions as protein kinase inhibitors
|
|
EP2608790A4
(en)
|
2010-08-26 |
2014-04-02 |
Glaxosmithkline Llc |
PHARMACEUTICAL COMBINATION OF A VEGFR-INHIBITOR AND A MEK-INHIBITOR FOR THE TREATMENT OF CANCER
|
|
CN101993415B
(zh)
|
2010-09-15 |
2013-08-14 |
北京韩美药品有限公司 |
作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用
|
|
AR083797A1
(es)
|
2010-11-10 |
2013-03-20 |
Novartis Ag |
Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
|
|
TWI505828B
(zh)
|
2010-12-20 |
2015-11-01 |
葛蘭素史克智慧財產（第二）有限公司 |
新穎醫藥組成物
|
|
KR101911972B1
(ko)
|
2011-02-07 |
2018-10-25 |
플렉시콘 인코퍼레이티드 |
키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
|
|
EP2686317A4
(en)
|
2011-03-17 |
2014-08-20 |
Selexagen Therapeutics Inc |
RAF KINASE INHIBITORS
|
|
WO2013022766A1
(en)
|
2011-08-05 |
2013-02-14 |
Flynn Gary A |
Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
|
|
CN103797011B
(zh)
|
2011-09-01 |
2016-03-30 |
诺华股份有限公司 |
作为c-Kit激酶抑制剂的化合物和组合物
|
|
ES2609606T3
(es)
|
2011-09-21 |
2017-04-21 |
Cellzome Limited |
Derivados de urea y carbamato de 2-morfolino-1,3,5-triazina como inhibidores de mTOR para el tratamiento de enfermedades inmunológicas o proliferativas
|
|
WO2013164769A1
(en)
|
2012-05-02 |
2013-11-07 |
Lupin Limited |
Substituted pyridine compounds as crac modulators
|
|
ES2670667T3
(es)
|
2012-05-15 |
2018-05-31 |
Novartis Ag |
Derivados de benzamida para inhibir la actividad de ABL1, ABL2 y BCR-ABL1
|
|
WO2014008214A1
(en)
|
2012-07-02 |
2014-01-09 |
Biogen Idec Ma Inc. |
Biaryl-containing compounds as inverse agonists of ror-gamma receptors
|
|
AR091876A1
(es)
|
2012-07-26 |
2015-03-04 |
Novartis Ag |
Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
|
|
TR201904980T4
(tr)
|
2012-08-07 |
2019-05-21 |
Novartis Ag |
Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar.
|
|
IN2015KN00449A
(https=)
|
2012-09-04 |
2015-07-17 |
Glaxosmithkline Llc |
|
|
US9914730B2
(en)
|
2012-09-28 |
2018-03-13 |
Cancer Research Technology Limited |
Azaquinazoline inhibitors of Atypical protein Kinase C
|
|
WO2014058691A1
(en)
|
2012-10-08 |
2014-04-17 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
|
US9867825B2
(en)
|
2012-12-20 |
2018-01-16 |
Novartis Ag |
Pharmaceutical combination comprising binimetinib
|
|
US9242969B2
(en)
*
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
|
UA118846C2
(uk)
|
2013-03-21 |
2019-03-25 |
Новартіс Аг |
Комбінована терапія
|
|
AU2014342338B2
(en)
|
2013-11-01 |
2016-12-01 |
Novartis Ag |
Aminoheteroaryl benzamides as kinase inhibitors
|
|
CA3240745A1
(en)
|
2013-12-20 |
2015-06-25 |
Biomed Valley Discoveries, Inc. |
Cancer treatment using combinations of erk and raf inhibitors
|
|
US10167279B2
(en)
|
2014-09-12 |
2019-01-01 |
Novartis Ag |
Compounds and compositions as RAF kinase inhibitors
|
|
UY36294A
(es)
|
2014-09-12 |
2016-04-29 |
Novartis Ag |
Compuestos y composiciones como inhibidores de quinasa
|
|
JP6646044B2
(ja)
|
2014-09-12 |
2020-02-14 |
ノバルティス アーゲー |
キナーゼ阻害剤としての化合物および組成物
|
|
WO2016115376A1
(en)
|
2015-01-14 |
2016-07-21 |
The Regents Of The University Of California |
Detection and treatment of double drug resistant melanomas
|
|
NZ735715A
(en)
|
2015-04-15 |
2022-09-30 |
Beigene Ltd |
Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
|
|
CN108368171A
(zh)
|
2015-07-10 |
2018-08-03 |
根马布股份公司 |
用于癌症治疗的axl特异性抗体-药物缀合物
|
|
US10328066B2
(en)
|
2015-08-28 |
2019-06-25 |
Novartis Ag |
Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer
|
|
WO2017037587A1
(en)
|
2015-08-28 |
2017-03-09 |
Novartis Ag |
Combination of ribociclib and dabrafenib for treating or preventing cancer
|
|
MX387795B
(es)
|
2016-06-03 |
2025-03-19 |
Array Biopharma Inc |
Combinaciones farmaceuticas.
|
|
AU2017279046B2
(en)
|
2016-06-10 |
2020-07-02 |
Novartis Ag |
Therapeutic uses of a c-Raf inhibitor
|
|
AU2017329090B9
(en)
|
2016-09-19 |
2019-09-05 |
Novartis Ag |
Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
|
|
WO2018107146A1
(en)
|
2016-12-11 |
2018-06-14 |
Memorial Sloan Kettering Cancer Center |
Methods and compositions for treatment of braf mutant cancers
|
|
ES2952265T3
(es)
|
2017-05-02 |
2023-10-30 |
Novartis Ag |
Terapia combinada que comprende un inhibidor de Raf y trametinib
|
|
AU2018269982B2
(en)
|
2017-05-16 |
2024-06-13 |
Biomed Valley Discoveries, Inc. |
Compositions and methods for treating cancer with atypical BRAF mutations
|
|
AU2018329925B2
(en)
|
2017-09-08 |
2025-05-29 |
F. Hoffmann-La Roche Ag |
Diagnostic and therapeutic methods for cancer
|
|
WO2020046966A1
(en)
|
2018-08-27 |
2020-03-05 |
Kura Oncology, Inc. |
Treatment of adenocarcinomas with mapk pathway inhibitors
|
|
JP2022514056A
(ja)
|
2018-12-20 |
2022-02-09 |
ノバルティス アーゲー |
癌の治療に使用するためのＲａｆ阻害剤及びＣＤＫ４／６阻害剤による組み合わせ療法
|
|
ES3025633T3
(en)
|
2019-05-13 |
2025-06-09 |
Novartis Ag |
New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
|
|
EP4106756A1
(en)
|
2020-02-18 |
2022-12-28 |
Novartis AG |
Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc
|
|
US20240000789A1
(en)
|
2020-05-12 |
2024-01-04 |
Novartis Ag |
Therapeutic combinations comprising a craf inhibitor
|
|
TW202227088A
(zh)
|
2020-08-31 |
2022-07-16 |
瑞士商諾華公司 |
組合療法
|